Delving into the Latest Updates on Xihua University with Synapse

Overview

Tags

Urogenital Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

No Data

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Top 5 Drug Type	Count

Small molecule drug	2

Top 5 Target	Count

SIRT5(NAD-dependent protein deacetylase sirtuin-5)	2

The anal. of uric acid (UA) in urine is adopted as a standard method for diagnosing related diseases, which provides an effective way for non-invasive detection of UA.However, no portable instruments presently can take an effective detection of UA in urine due to their detection limit, the indicator mainly impacted by sensitive materials.Hence, it is crucial to design electrochem. biosensor electrode materials with high sensitivity and the wide linear region for the detection of UA in urine.This research critically reveals a snowflake-like complex by simply combining the cerium-based metal-organic framework (Ce-BTC) and MoS₂.The excellent electrochem. performance of Ce-BTC@MoS₂ origins from the strong interfacial electronic interactions between Ce-BTC and MoS₂ heterojunction and abundant active sites for UA oxidationThe Ce-BTC@MoS₂ exhibits sensitivity (300.29 μA mM^-1cm^-2) for UA much higher than that of pristine Ce-BTC (129.14 μA mM^-1cm^-2) as well as MoS₂ (209.71 μA mM^-1cm^-2) in the linear region from 5 to 2500 μM.The outstanding selectivity, excellent stability and attractive repeatability of the UA sensor fabricated by Ce-BTC@MoS₂ have been also demonstrated, on account of the unique heterojunction of the electrode material.Addnl., the extensive linear region (0.5-4.4 mM) for the Ce-BTC@MoS₂ sensor will be employed to analyze the concentration of UA in urine which can be directly measured without being processed.The prepared urine UA detector combined with the com. blood UA detector provides an important basis for the comprehensive UA detection and clin. diagnosis.

01 Jan 2025·Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy

Strong near-infrared upconversion luminescence of the Er3+/Y3+ co-doped YbVO4 phosphor for multimode optical temperature measurement

Article

Author: Duan, Bin ; Hu, Junshan ; Ding, Changchun ; Li, Yongqiang ; Zhu, Daobin ; Wu, Yuxiang

This study explored the enhancement of near-infrared emissions in YbVO₄: Er³⁺ through Y³⁺ ion doping under a 980 nm laser excitation. The phosphor exhibits weak green emissions at 527 nm (²H_11/2 → ⁴I_15/2) and 553 nm (⁴S_3/2 → ⁴I_15/2), red emissions at 654 nm (⁴F_9/2 → ⁴I_15/2), and a strong near-infrared emission at 803 nm (⁴I_9/2 → ⁴I_15/2). Optimal doping concentration of Y³⁺ ion in YbVO₄: 0.02 Er³⁺ was determined to be 0.1, resulting in a 7.6-fold enhancement of near-infrared luminescence. This enhancement is attributed to defect bands facilitating energy transfer from green and red levels to the near-infrared levels. Furthermore, a multi-mode temperature sensor based on YbVO₄: Er³⁺/Y³⁺ was developed, offering four distinct temperature sensing modes: TCEL of ²H_11/2/⁴S_3/2, NTCEL of ²H_11/2/⁴F_9/2 and ⁴S_3/2/⁴F_9/2, and single luminescence emission intensity of ⁴I_9/2 energy level. The sensor demonstrates maximum relative sensitivities of 1.17 % K^-1 at 298 K, 0.66 % K^-1 at 298 K, 0.41 % K^-1 at 298 K and 1.29 % K^-1 at 673 K. YbVO₄: Er³⁺/Y³⁺ phosphor exhibits high temperature sensitivity, showcasing significant potential for optical temperature sensing applications.

01 Jan 2025·Food Hydrocolloids

Probiotics encapsulated by calcium pectin/chitosan-calcium pectin/sodium alginate-pectin-whey through biofilm-based microencapsulation strategy and their preventive effects on ulcerative colitis

Author: Deng, Jia ; Zhang, Chengyi ; Rao, Yu ; Liu, Lei ; Song, Yunlong

Biofilm-based probiotics have emerged as a compelling approach for administering probiotics.Selecting appropriate wall materials for enclosing probiotics in biofilm structure is viewed as an advanced method of microencapsulation.In this study, Lactiplantibacillus paraplanturm LR-1 was enclosed in three different types of wall materials to create calcium pectin beads (CPB), chitosan-calcium pectin beads (C-CPB), and sodium alginate-pectin-whey beads (SPW).The biofilm cells of LR-1 were cultured externally and then encapsulated to create CPB-ex-LR-1, C-CPB-ex-LR-1 and SPW-ex-LR-1.In contrast, LR-1 was cultured within the microcapsules to form biofilms in situ, resulting in CPB-situ-LR-1, C-CPB-situ-LR-1 and SPW-situ-LR-1.The microcapsules displayed a relatively uniform morphol. with the water contents below 10%.Nevertheless, there were noticeable edge effects in the distribution of strains within the in situ-type microcapsules.The detection of distinctive peaks unique to Lactiplantibacillus within the microcapsules confirmed the successful encapsulation.Addnl., a decrease in the intensity of the peaks linked to the wall materials indicated the formation of an amorphous structure within the microcapsules.The bacterial concentrations of situ-type microcapsules were found to surpass 10 lg CFU/g.The SPW-situ-LR-1 demonstrated superior tolerance performance, optimal release properties in simulated gastrointestinal fluids, and exceptional stability during the storage period.Addnl., SPW-situ-LR-1 showed similar effectiveness in alleviating colitis compared to fresh Biofilm-LR-1.Both Biofilm-LR-1 and SPW-situ-LR-1 pre-treatments exhibited pos. effects on regulation, with SPW-situ-LR-1 administration significantly increasing the presence of Lactobacillus.This study provides valuable insights into the development of the next-generation probiotics.

100 Deals associated with Xihua University

Login to view more data

100 Translational Medicine associated with Xihua University

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

2

Login to view more data